B
Bart Barlogie
Researcher at Mount Sinai Hospital
Publications - 47
Citations - 6242
Bart Barlogie is an academic researcher from Mount Sinai Hospital. The author has contributed to research in topics: Multiple myeloma & Gene expression profiling. The author has an hindex of 18, co-authored 47 publications receiving 5939 citations. Previous affiliations of Bart Barlogie include Millennium Pharmaceuticals & University of Arkansas for Medical Sciences.
Papers
More filters
Book ChapterDOI
Imaging of Multiple Myeloma, Solitary Plasmacytoma, MGUS, and Other Plasma Cell Dyscrasias
TL;DR: Recent work has established the fundamental importance of 18F-FDG PET and PET/CT for the baseline evaluation of patients with multiple myeloma and related plasma cell dyscrasias, as well as for subsequent evaluations related to patient management.
Journal ArticleDOI
Race-Dependent Differences in Risk, Genomics, and Epstein–Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120
Madhav V. Dhodapkar,Rachael Sexton,Antje Hoering,Frits van Rhee,Bart Barlogie,Robert Z. Orlowski +5 more
TL;DR: These data provide the first prospective evidence that multiple myeloma precursor states in AA patients may have lower risk of disease compared with non-AA counterparts with lower incidence of high-risk GEP and increased EBV seropositivity.
Journal ArticleDOI
Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups.
Eileen M Boyle,Adam Z. Rosenthal,Hussein Ghamlouch,Yan Wang,Phillip Farmer,Michael E. Rutherford,Cody Ashby,Michael A Bauer,Sarah K. Johnson,Christopher P. Wardell,Yubao Wang,Antje Hoering,Carolina Schinke,Sharmilan Thanendrarajan,Maurizio Zangari,Bart Barlogie,Madhav V. Dhodapkar,Faith E. Davies,Gareth J. Morgan,Frits van Rhee,Brian A Walker +20 more
TL;DR: In this paper, the authors investigated 223 SMM and 1348 MM samples from the University of Arkansas for Medical Sciences (UAMS) for which they had gene expression profiling (GEP).
Journal ArticleDOI
PHF19 inhibition as a therapeutic target in multiple myeloma
Carolina Schinke,Jordan T. Bird,Pingping Qu,Shmuel Yaccoby,Valeriy V. Lyzogubov,Randal S Shelton,Wen Ling,Eileen M Boyle,Sharyu Deshpande,Stephanie D. Byrum,Charity L. Washam,Samuel G. Mackintosh,Owen W. Stephens,Sharmilan Thanendrarajan,Maurizio Zangari,John D. Shaughnessy,Fenghuang Zhan,Bart Barlogie,Frits van Rhee,Brian A Walker +19 more
TL;DR: In this paper, a functional knockdown (KD) of PHD finger protein 19 (PHF19), a subunit of the Polycomb Repressive Complex 2 (PRC2), has been used to investigate the biological role of PHF19 and show that PHF 19KD leads to decreased tumor growth in vitro and in vivo.
Patent
Diagnosis, prognosis, identification, and classification of multiple myeloma based on gene expression profiling
TL;DR: In this article, a method for gene expression profiling multiple myeloma patients into distinct subgroups via DNA hybridization and hierarchical clustering analysis of the hybridization data where the results may further be used to identify therapeutic gene targets.